Synergistic tumor growth inhibition by combined treatment with green tea epigallocatechin-3-gallate (EGCG) and an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), erlotinib in squamous cell carcinoma of the head and neck (SCCHN)